Application of carbon nanotubes as the carriers of the cannabinoid, 2-arachidonoylglycerol: Towards a novel treatment strategy in colitis

Life Sciences

Volumn 179, Issue , 2017, Pages 66-72

  Hassanzadeh, Parichehr ^a   Arbabi, Elham ^b   Atyabi, Fatemeh ^a   Dinarvand, Rassoul ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

2 arachidonoyglycerol; Carbon nanotubes; Colitis; Rat

Indexed keywords

2 ARACHIDONOYLGLYCEROL; INTERLEUKIN 1BETA; MALONALDEHYDE; MULTI WALLED NANOTUBE; MYELOPEROXIDASE; NANOCARRIER; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR; ACYLGLYCEROL; ARACHIDONIC ACID DERIVATIVE; CANNABINOID RECEPTOR AGONIST; CARBON NANOTUBE; ENDOCANNABINOID; GLYCERYL 2-ARACHIDONATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLON INJURY; COLON TISSUE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; DRUG STABILITY; ENZYME ACTIVITY; IN VITRO STUDY; INFRARED SPECTROSCOPY; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; THERAPY EFFECT; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; INFLAMMATION; PATHOLOGY; WISTAR RAT;

ANIMALS; ARACHIDONIC ACIDS; CANNABINOID RECEPTOR AGONISTS; COLITIS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; ENDOCANNABINOIDS; GLYCERIDES; INFLAMMATION; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOTUBES, CARBON; OXIDATIVE STRESS; RATS; RATS, WISTAR; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TRINITROBENZENESULFONIC ACID;

EID: 85018440891     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2016.11.015     Document Type: Article

References (36)

1. [1] Podolsky, D.K., Inflammatory bowel disease. N. Engl. J. Med. 347 (2002), 417–429.
2. [2] Waetzig, G.H., Seegert, D., Rosenstiel, P., Nikolaus, S., Schreiber, S., p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J. Immunol. 168 (2002), 5342–5351.
3. [3] Vagefi, P.A., Longo, W.E., Colorectal cancer in patients with inflammatory bowel disease. Clin. Colorectal Cancer 4 (2005), 313–319.
4. [4] Wewer, V., Gluud, C., Schlichting, P., Burcharth, F., Binder, V., Prevalence of hepatobiliary dysfunction in a regional group of patients with chronic inflammatory bowel disease. Scand. J. Gastroenterol. 26 (1991), 97–102.
5. [5] Lossos, A., River, Y., Eliakim, A., Steiner, I., Neurologic aspects of inflammatory bowel disease. Neurology 45 (1995), 416–421.
6. [6] Kucharzik, T., Maaser, C., Lugering, A., Kagnoff, M., Mayer, L., Targan, S., et al. Recent understanding of IBD pathogenesis: implications for future therapies. Inflamm. Bowel Dis. 12 (2006), 1068–1083.
7. [7] van Deventer, S.J.H., Inflammatory bowel disease: future therapies. Curr. Treat Options Gastroenterol. 5 (2002), 207–212.
8. [8] Di Marzo, V., Piscitelli, F., Gut feelings about the endocannabinoid system. Neurogastroenterol. Motil. 23 (2011), 391–398.
9. [9] Sanson, M., Bueno, L., Fioramonti, J., Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol. Motil. 18 (2006), 949–956.
10. [10] Massa, F., Storr, M., Lutz, B., The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. J. Mol. Med. (Berl) 83 (2005), 944–954.
11. [11] Storr, M.A., Keenan, C.M., Emmerdinger, D., Zhang, H., Yuce, B., Sibaev, A., et al. Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J. Mol. Med. 86 (2008), 925–936.
12. [12] Engel, M.A., Kellermann, C.A., Burnat, G., Hahn, E.G., Rau, T., Konturek, P.C., Mice lacking cannabinoid CB1-, CB2-receptors or both receptors show increased susceptibility to trinitrobenzene sulfonic acid (TNBS)-induced colitis. J. Physiol. Pharmacol. 61 (2010), 89–97.
13. [13] Howlett, A.C., Barth, F., Bonner, T.I., Cabral, G., Casellas, P., Devane, W.A., et al. International Union of Pharmacology XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54 (2002), 161–202.
14. [14] Alhouayek, M., Masquelier, J., Muccioli, G.G., Controlling 2-arachidonoylglycerol metabolism as an anti-inflammatory strategy. Drug Discov. Today 19 (2014), 295–304.
15. [15] Christopher, P.S., O'Sullivan, S.E., Cyclooxygenase metabolism mediates vasorelaxation to 2-arachidonoylglycerol (2-AG) in human mesenteric arteries. Pharmacol. Res. 81 (2014), 74–82.
16. [16] Alhouayek, M., Lambert, D.M., Delzenne, N.M., Cani, P.D., Muccioli, G.G., Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. FASEB J. 25 (2011), 2711–2721.
17. [17] Blankman, J.L., Simon, G.M., Cravatt, B.F., A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 14 (2007), 1347–1356.
18. [18] Kam, N.W., Dai, H., Carbon nanotubes as intracellular protein transporters: generality and biological functionality. J. Am. Chem. Soc. 127 (2005), 6021–6026.
19. [19] Fabbro, A., Bosi, S., Ballerini, L., Prato, M., Carbon nanotubes: artificial nanomaterials to engineer single neurons and neuronal networks. ACS Chem. Neurosci. 3 (2012), 611–618.
20. [20] Son, S.J., Bai, X., Nan, A., Ghandehari, H., Lee, S.B., Template synthesis of multifunctional nanotubes for controlled release. J. Control. Release 114 (2006), 143–152.
21. [21] Lee, H.J., Park, J., Yoon, O.J., Kim, H.W., Lee do, Y., Kim do, H., et al. Amine-modified single-walled carbon nanotubes protect neurons from injury in a rat stroke model. Nat. Nanotechnol. 6 (2011), 121–125.
22. [22] Hamdi, H., De La Torre-Roche, R., Hawthorne, J., White, J.C., Impact of non-functionalized and amino-functionalized multiwall carbon nanotubes on pesticide uptake by lettuce (Lactuca sativa L.). Nanotoxicology 9 (2015), 172–180.
23. [23] Chen, W., Xiong, Q., Ren, Q., Guo, Y., Li, G., Can amino-functionalized carbon nanotubes carry functional nerve growth factor?. Neural Regen. Res. 9 (2014), 285–292.
24. [24] Mosmann, T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983), 55–63.
25. [25] Abdel-Salam, O., Gastric acid inhibitory and gastric protective effects of cannabis and cannabinoids. Asian Pac J Trop Med 9 (2016), 413–419.
26. [26] Varga, K., Wagner, J.A., Bridgen, D.T., Kunos, G., Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J. 12 (1998), 1035–1044.
27. [27] Morris, G.P., Beck, P.L., Herridge, M.S., Depew, W.T., Szewczuk, M.R., Wallace, J.L., Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96 (1989), 795–803.
28. [28] McCafferty, D.M., Sharkey, K.A., Wallace, J.L., Beneficial effects of local or systemic lidocaine in experimental colitis. Am. J. Physiol. Gastrointest. Liv. Physiol. 266 (1994), G560–G567.
29. [29] Conklin, L.S., Centola, M., Li, X., Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm. Bowel Dis. 15 (2009), 341–352.
30. [30] Bradley, P.P., Priebat, D.A., Christensen, R.D., Rothstein, G., Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J. Invest. Dermatol. 78 (1982), 206–209.
31. [31] Rungby, J., Flyvbjerg, A., Andersen, H.B., Nyborg, K., Lipid peroxidation in early experimental diabetes in rats: effects of diabetes and insulin. Acta Endocrinol. 126 (1992), 378–380.
32. [32] Sandborn, W.J., Strategies targeting tumor necrosis factor in Crohn's disease. Acta Gastroenterol. Belg. 64 (2001), 170–172.
33. [33] Nilsen, E.M., Johansen, F.E., Jahnsen, F.L., Lundin, K.E., Scholz, T., Brandtzaeg, P., et al. Cytokine profiles of cultured microvascular endothelial cells from the human intestine. Gut 42 (1998), 635–642.
34. [34] Targan, S.R., Hanauer, S.B., van Deventer, S.J., Mayer, L., Present, D.H., Braakman, T., A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease, Crohn's disease cA2 study group. N. Engl. J. Med. 337 (1997), 1029–1035.
35. [35] Yoshikawa, T., Naito, Y., Kishi, A., Tomii, T., Kaneko, T., Iinuma, S., et al. Role of active oxygen, lipid peroxidation, and antioxidants in the pathogenesis of gastric mucosal injury induced by indomethacin in rats. Gut 34 (1993), 732–737.
36. [36] Whan, L.B., West, M.C., McClure, N., Lewis, S.E., Effects of Δ-9-tetrahydrocannabinol, the primary psychoactive cannabinoid in marijuana, on human sperm function in vitro. Fertil. Steril. 85 (2006), 653–660.